Study of changes in blood and urine purine compounds by the administration of SG-1 (Compound A and B) or either of them.
- Conditions
- ormal adult males
- Registration Number
- JPRN-UMIN000022455
- Lead Sponsor
- Tsukuba International Clinical Pharmacology Clinic
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- Male
- Target Recruitment
- 22
Not provided
1) Routine user of medicine or supplement. 2) Subject who is currently being treated. 3) Subject who has or had renal function disorder. 4) Subject with a history of gout, hyperuricemia or urolithiasis. 5) Subject who has a history of renal disorder. 6) Subject who has or had hypersensitivity, idiosyncracy (allergy) to drug. 7) Subject with a disease or a disorder in heart, kidney, pulmonary organ, digestive organ or blood function that are considered to affect absorption, distribution, metabolism or excretion of a drug. 8) Subject who participated in another clinical study for a drug with a new compound within 4 weeks before the administration of drug in the present sduty. 9) Subject who donated 400 mL of blood within 12 weeks, 200 mL of blood within 4 weeks or blood components within 2 weeks. 10) Subject who used other drugs (including herbs) or supplements within 2 weeks before the administration of drug in this study. 11) Sujbect who plans to take other drugs (including herbs) or supplements before the end of the present study. 12) Subject who was judged not to be appropriate by the principal investigator or sub investigators by other reasons.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Changes of blood and urine purine compounds at 14 days after the daily administration of drugs
- Secondary Outcome Measures
Name Time Method